Bensonburton5867

72, 95% CI = 0.53-0.98, P = .039; aHR = 0.73, 95% CI = 0.586-0.92, P = .006; and aHR = 0.71, 95% CI = 0.56-0.90, P = .004; respectively). Cetuximab However, DES placement had a neutral effect on the risk of new-onset AF in the patients with STEMI.Compared with the use of BMS, the use of DES might reduce the risk of new-onset AF in patients with NSTEMI.Thyroid cancer (TC) is the most well-known endocrine neoplasia as well as a common malignant tumor in the head and neck. Our study was designed to assess the prognostic meaningful of TNFRSF12A expression in TC dependent on data acquired from TCGA and so as to increase further knowledge into the biological pathways involved in TC pathogenesis related TNFRSF12A.Information on gene expression and comparing clinical data were identified and downloaded from TCGA. Gene set enrichment analysis (GSEA) created an arranged list of all genes indicated by their connection with TNFRSF12A expression.Our study cohort included 370 (73.1%) female and 136 (26.9%) male patients. The scatter plot and paired plot showed the difference of TNFRSF12A expression between normal and tumor samples (P  less then  .01). The univariate analysis suggested that TNFRSF12A-low associated essentially with age (HR 1.15; 95%CI 1.08-1.22; P  less then  .01), stage (HR 2.79; 95%CI 1.43-5.46; I vs IV; P = .003) and tumor stage (HR 2.39; 95%CI 1.08-5.30; P = .031). The GSEA results show that type II diabetes mellitus, pantothenate and CoA biosynthesis, adipocytokine signaling pathway, PPAR signaling pathway, mTOR signaling pathway, insulin signaling pathway, are enriched in TNFRSF12A low expression phenotype.TNFRSF12A expression may be a potential useful prognostic molecular biomarker of bad survival in thyroid cancer, in addition, PPAR signaling pathway, insulin signaling pathway, mTOR signaling pathway may be the key pathway controlled by TNFRSF12A in thyroid cancer. Further experimental ought to be performed to demonstrate the biologic effect of TNFRSF12A.

Chinese herbal medicine (CHM) has been widely used to treat knee osteoarthritis (KOA), among which Yanghe decoction (YHD) is one of the commonly used prescriptions. The purpose of this study is to evaluate the effectiveness and safety of YHD in the treatment of KOA.

Six databases, including Embase, PubMed, the Cochrane Library, the China National Knowledge Infrastructure, Wanfang Database and Chinese Science and Technology Periodical Database will be searched from their inception to July 2020. Two researchers will independently select studies, collect data and evaluate the quality of included studies. Statistical analysis will be processed by RevMan V.5.3 software.

This study will provide an assessment of the current state of YHD in the treatment of KOA, aiming to show the efficacy and safety of YHD.

This study will provide evidence to judge whether YHD is an effective intervention for KOA.

This study will provide evidence to judge whether YHD is an effective intervention for KOA.

Cancer continues to be a severe global health problem and the leading cause of death worldwide. Chemotherapy as the main treatment has various side effects, of which marrow suppression is the most common one. Acupuncture had shown clinical effects for marrow suppression after chemotherapy in many studies. However, the efficacy and safety of acupuncture therapy for marrow suppression after chemotherapy remains unclear.

This protocol aims to evaluate the efficacy and safety of acupuncture for marrow suppression after chemotherapy according to the existing randomized controlled trials.

The randomized controlled trials on acupuncture therapy for marrow suppression after chemotherapy will be searched in the database of Embase, PubMed and Cochrane Library, Allied and Complementary Medicine Database (AMED), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), WanFang Database (WF), and related registration platforms (ion after chemotherapy.

PROSPERO CRD42020163336.

PROSPERO CRD42020163336.

Coronavirus disease 2019 (COVID-19) has caused serious damage to public health. COVID-19 has no vaccine or specific therapy; its mortality rate increases significantly once patients deteriorate. Furthermore, intensive monitoring of COVID-19 is limited by insufficient medical resources and increased risks of exposure to medical staff. We therefore aim to build an early warning and rapid response system (EWRRS) to address these problems.

The research is designed as a prospective cohort study, to verify a dynamic and interactive evaluation system; it includes patient self-reporting, active monitoring, early alarming and treatment recommendations. Adult patients diagnosed with COVID-19 will be recruited from Sept 2020 to Aug 2021 at a tertiary contagious hospital. Patients with life expectancy <48 hours, pregnant or lactating, in immunosuppression states or end-stage diseases will be excluded. The intervention is implementation of EWRRS to detect early signs of clinical deterioration of COVID-19 patients, ICU setting.

Our hypothesis is that EWRRS provides an example of an early identification, warning, and response system for COVID-19. In addition, EWRRS can potentially be extended to use as a grading metric for general critically ill patients in an ICU setting.

Coronavirus disease 2019 (COVID-19), a new type of coronavirus, first reported in Wuhan, China at the end of December 2019. As a result of the worldwide outbreak, the number of patients continues to increase. With multiple therapeutic interventions, more and more patients are recovering. Fire needle is used as an alternative therapy. At present, there are no relevant articles for systematic review and meta-analysis, so this study will evaluate the efficacy and safety of fire needle in the treatment of COVID-19 pneumonia.

The following electronic bibliographic databases will be searched to identify relevant studies from December 2019 to December 2020 MEDLINE, PubMed, Embase, Cochrane library, Web of Science, China National Knowledge Infrastructure (CNKI), Chinese Technical Periodicals (VIP), Wan-fang data, Chinese Biological Medicine Database (CBM), and other databases. All included articles were randomized controlled trial without any language restrictions. Two reviewers will independently conduct cations retrieval, de-duplication, filtering, quality assessment, and data analysis by the Review Manager (V.